EQS-News: Zur Rose Group AG: Statement on the draft coalition agreement in Germany: Rx mail-order ban not to be justified
07.02.2018 (www.4investors.de) -
EQS Group-News: Zur Rose Group AG / Key word(s): Statement
Zur Rose Group AG: Statement on the draft coalition agreement in Germany: Rx mail-order ban not to be justified
07.02.2018 / 17:49
Statement on the draft coalition agreement in Germany: Rx mail-order ban not to be justified
As per the draft coalition agreement of the parties CDU/CSU and SPD published today the parties intend to implement a ban on mail-order of prescription drugs in order to strengthen local pharmacies. Based on expert opinions and statements of previous federal governments, the Zur Rose Group remains convinced that this intention is unconstitutional and incompatible with European law. The company is therefore very surprised that these assessments were apparently not sufficiently considered and that this intention was included in the draft coalition agreement. In the interest of patients the Zur Rose Group will therefore take all necessary legal and operative steps both in Germany and at European level.
Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail: email@example.com, telephone: +41 52 724 00 64
Lisa Lüthi, Head of Corporate Communications
e-mail: firstname.lastname@example.org, telephone: +41 52 724 08 14
Zur Rose Group
Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose Group is Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care. while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.
The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. Customers in Germany and Austria are primarily supplied from Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 1000 people at its various locations, Zur Rose Group generated revenue of CHF 983 million in 2017. Zur Rose Group AG's shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange. More information at zurrosegroup.com.
End of Corporate News
Zur Rose Group AG
+41 52 724 08 14
SIX Swiss Exchange
End of News
EQS Group News Service
Probiodrug: Drei entscheidende Jahre im Kampf gegen Alzheimer
Gigaset: „Werden bald eine ganz neue Art von Kommunikation erleben“